GLP-1 vs. dual and triple agonists: what's the difference?

GLP-1 (glucagon-like peptide-1) is a gut hormone that slows gastric emptying, increases satiety, and improves insulin response. GLP-1 receptor agonists mimic that signal.

GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone. Dual agonists act on both GLP-1 and GIP receptors. Triple agonists add glucagon-receptor activity, which is associated with increased energy expenditure in trials.

More receptor targets generally correlates with greater average weight reduction in clinical studies, but also with a different side-effect and titration profile. Average results are not individual results.

Nausea, reflux, constipation, and fatigue are the most commonly reported effects across this class, and are usually managed by slowing titration.

Most patients start at a low dose and titrate upward over several weeks. Appetite changes are often noticed within the first two to four weeks; meaningful weight change is typically assessed over three to six months.

Weight regain after stopping is common across the class, which is why providers plan maintenance rather than a fixed end date.

These medications are generally avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, in pregnancy, and in active pancreatitis. Your provider will screen for these during intake.

Compounded formulations are prepared by licensed US pharmacies for an individual patient and are not FDA-approved products. That distinction matters and should be part of your decision.